Lestaurtinib Completed Phase 2 Trials for Psoriasis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00236119Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis